Target Area:
Vestibular and balance disorders
Cinnarizine is a well-established agent for the management of vertigo, motion sickness, and vestibular dysfunction, combining antihistaminic and calcium channel-blocking activity.
Our development approach prioritizes robust process design, consistent API quality, and long-term supply reliability for pharmaceutical applications.
"Aurapha’s science-driven approach to API development demonstrates how rigorous chemistry, process robustness, and regulatory readiness can translate complex molecules into reliable, scalable drug substances."